Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Processa Pharmaceuticals (NASDAQ: PCSA) announced its participation in two upcoming investor conferences. The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is scheduled for September 22, 2021, at 9:05 AM (ET), with a webcast available here. The Cantor Fitzgerald Healthcare Conference will follow on September 29, 2021, at 10:40 AM (ET), with a webcast accessible here. One-on-one investor meetings will also be hosted during these events.

HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in upcoming investor conferences: 

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

• Date and Time: 9/22/2021 9:05 AM (ET)
• Webcast: https://wsw.com/webcast/oppenheimer16/pcsa/2763189
• Management will also host 1x1 investor meetings during the conference. 
  

Cantor Fitzgerald Healthcare Conference

• Date and Time: 9/29/2021 10:40 AM (ET)
• Webcast: https://wsw.com/webcast/cantor12/pcsa/2072070
• Management will also host 1x1 investor meetings during the conference.
  

To schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.

About Processa Pharmaceuticals, Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

Forward-Looking Statements

This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.

For More Information: 
Michael Floyd 
mfloyd@processapharma.com
301-651-4256

James Carbonara 
Hayden IR 
(646) 755-7412 
james@haydenir.com

FAQ

What is the date of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit for Processa Pharmaceuticals?

The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is on September 22, 2021, at 9:05 AM (ET).

When will Processa Pharmaceuticals present at the Cantor Fitzgerald Healthcare Conference?

Processa Pharmaceuticals will present at the Cantor Fitzgerald Healthcare Conference on September 29, 2021, at 10:40 AM (ET).

Where can I find the webcast for Processa Pharmaceuticals' upcoming investor conferences?

The webcast for the Oppenheimer conference can be found here, and the Cantor Fitzgerald conference webcast is available here.

Will Processa Pharmaceuticals hold one-on-one meetings during the conferences?

Yes, Processa Pharmaceuticals will host one-on-one investor meetings during both conferences.